Insider Selling: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Sells $54,352.00 in Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Amy E. Mckee sold 8,600 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $6.32, for a total transaction of $54,352.00. Following the sale, the director now directly owns 27,831 shares of the company’s stock, valued at $175,891.92. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $6.11 on Friday. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $7.95. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -5.71 and a beta of 1.88. The firm has a fifty day moving average of $5.75 and a 200-day moving average of $5.63.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same quarter in the prior year, the company posted ($0.28) EPS. The company’s quarterly revenue was up 34.9% compared to the same quarter last year. On average, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. JMP Securities increased their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.00.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently made changes to their positions in BCRX. Braidwell LP raised its stake in shares of BioCryst Pharmaceuticals by 92.1% in the 3rd quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock valued at $37,970,000 after buying an additional 2,571,100 shares in the last quarter. Vanguard Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 15.4% during the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock worth $106,405,000 after purchasing an additional 2,371,401 shares in the last quarter. Norges Bank acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $13,278,000. Deerfield Management Company L.P. Series C increased its position in shares of BioCryst Pharmaceuticals by 148.6% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock worth $23,265,000 after purchasing an additional 1,964,000 shares in the last quarter. Finally, Kynam Capital Management LP increased its position in shares of BioCryst Pharmaceuticals by 41.9% during the 1st quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock worth $33,160,000 after purchasing an additional 1,927,491 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.